Biotechnology company PerkinElmer has announced its documentation, workflow and decision-making informatics platform, Signals, is expanding to build on existing capabilities in the biologics drug discovery space. This comes through a collaboration with Insightful Science, a software company serving the global life sciences community.
With the collaboration, pharmaceutical and academic research teams can combine the power of the Signals platform with solutions from Insightful Science’s Bioinformatics division. This includes SnapGene and Geneious Prime software offerings that enable molecular biologists design and execute DNA construct design, molecular cloning and other kinds of molecular biology research.
The integration will give scientists the ability to access and compare data across experiments and instruments, and collaborate more intuitively. They can also replicate assays and experiments instantly, leading to faster time-to-result and more informed decision making on drug and vaccine targets.
Kevin Willoe, VP and GM of PerkinElmer, Informatics, said: “Through our collaboration with Insightful Science, we’re able to provide enhanced informatics capabilities to scientists doing vital biologics and vaccine research. This will help significantly reduce cycle times for researchers and aid them in making data-driven decisions faster and more accurately – important capabilities when fighting foes like cancer, cardio, neurological and viral diseases.”
Brett Ammundsen, CEO Bioinformatics at Insightful Science, said: “The combination of SnapGene and Geneious Prime software with the PerkinElmer Signals platform powerfully enhances research workflows and enriches collaboration. Ultimately this will better connect scientists to their ideas and data, so they can focus o
